Inquire About a Product| Product: | Everolimus-d4 | ||||
|---|---|---|---|---|---|
| Catalog Number: | D10193 | ||||
| CAS Number: | 1338452-54-2 | ||||
| Synonyms: | 42-O-(2-Hydroxyethyl-d4)rapamycin; RAD-001-d4; Certican-d4 | ||||
| Pricing: |
|
||||
| Formula: | C53H79D4NO14 | ||||
| Enrichment: | 98%D | ||||
| Chemical Purity: | 98% | ||||
| Molecular Weight: | 962.25 | ||||
| Structure: |
|
||||
| Appearance: | Off-white solid | ||||
| Category: | Labeled Reference Standards | ||||
| Stability: | Stable under recommended storage conditions | ||||
| Storage: |
Keep container tightly closed in a dry and well ventilated place. Store at -20°C under inert atmosphere |
||||
| Literature References: |
R.N Formica Jra, K.M Lorberb, A.L Friedmanb, M.J Biaa, F Lakkisa, J.D Smitha, M.I Lorber, The evolving experience using everolimus in clinical transplantation. Elsevier, 2004, 36 (2): S495–S499.; Lutz M, Kapp M, Grigoleit GU, Stuhler G, Einsele H, Mielke S., Salvage therapy with everolimus improves quality of life in patients with refractory chronic graft-versus-host disease. Bone Marrow Transplant, 2012, 47 (S1): S410–S411. |
||||
| MSDS: | |||||
| Description: | A labeled derivative of sirolimus. Inhibits mammalian target of rapamycin. Used as an immunosuppressant to prevent rejection of organ transplants and treatment of renal cell cancer. |